-

INSERTING and REPLACING Delaware Protest: Advocates Stand Up Against AstraZeneca to Save Drug Discount Program for Vulnerable Populations

Wilmington Protest, Wed., Oct. 14th - 12 noon – 1:00 pm ET

Dozens of concerned healthcare advocates from across the northeast region protest AstraZeneca, one of five U.S. based pharmaceutical companies that have cut back on the number of drugs they provide through the 340B federal drug discount program

WILMINGTON, Del.--(BUSINESS WIRE)--Please replace the release with the following updated version due to multiple revisions.

The updated release reads:

DELAWARE PROTEST: ADVOCATES STAND UP AGAINST ASTRAZENECA TO SAVE DRUG DISCOUNT PROGRAM FOR VULNERABLE POPULATIONS

Wilmington Protest, Wed., Oct. 14th - 12 noon – 1:00 pm ET

Dozens of concerned healthcare advocates from across the northeast region protest AstraZeneca, one of five U.S. based pharmaceutical companies that have cut back on the number of drugs they provide through the 340B federal drug discount program.

Healthcare advocates from across the northeast region will protest the recent actions of AstraZeneca, in cutting back the number of critical life-saving drugs provided at discounted rates to non-profit healthcare providers, through the federal 340B drug discount program.

WHAT:

Protest against AstraZeneca

 

 

WHERE:

AstraZeneca’s Corporate Office

 

1800 Concord Pike, Wilmington, DE 19803

 

NOTE: The protest will take place at the intersection of Powder Mill Road & Route 22

 

 

WHEN:

Tomorrow, Wednesday, October 14, 2020

 

12noon – 1pm (EDT)

 

 

WHO:

Healthcare advocates from across the Northeast Region

The federal 340B Drug Discount Program is a lifeline that allows safety net providers, including HIV/AIDS clinics receiving funding through the Ryan White program, to obtain prescription drugs at below-retail prices. The program was established with bipartisan support as part of the Veterans Health Care Act of 1992. With 340B savings, Ryan White clinics are able to stretch their grant funds, offer a wider range of services, and improve the quality of care persons living with HIV/AIDS receive. The program also benefits qualified 340B covered entities such as non-profit rural health facilities, community clinics and children’s hospitals that serve vulnerable populations.

Tomorrow’s protest, led by healthcare advocates from AIDS Healthcare Foundation (AHF), follows a lawsuit filed by Ryan White Clinics for 340B Access (RWC-340B) against the U.S. Department of Health and Human Services (HHS), in U.S. District Court for the District of Columbia, to require the HHS secretary to take action against AstraZeneca and three other pharmaceutical companies, including Eli Lilly, Novartis and the U.S. division of Sanofi-Aventis which are illegally withholding drugs they are required to sell through the 340B program. With tomorrow’s protest, AHF is demanding that these greedy pharmaceutical companies stop their bullying tactics that will have a devastating impact on the healthcare and well-being of our most vulnerable populations (see LITIGATION PRESS RELEASE). RWC340B also recently released a study on the potential adverse impact of policies reducing resources to Ryan White clinics, see WHITE PAPER, PRESS RELEASE, and FACT SHEET.

“AstraZeneca has launched an assault on a federal drug discount program essential to the safety net of our nation’s health care,” stated John Hassell, AHF’s national director of advocacy. “They are messing with the numerous health care centers and hospitals on the front-lines of the COVID-19 pandemic, and denying discount drugs to these facilities, required by law, just to increase their profits. Why can’t AstraZeneca put people over profits?”

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.4 million individuals in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us @aidshealthcare.

Contacts

MEDIA CONTACTS:
AHF HQ: Ged Kenslea, Senior Director, Communications, AHF
+1.323.791.5526 [cell]; +1.323.308.1833 [work]; gedk@aidshealth.org
AHF East Coast: Imara Canady, National Director, Communications and Community Engagement, AHF
+1.470.639.6591 work; +1.770.940.6555 mobile; imara.canady@ahf.org

AIDS Healthcare Foundation


Release Versions

Contacts

MEDIA CONTACTS:
AHF HQ: Ged Kenslea, Senior Director, Communications, AHF
+1.323.791.5526 [cell]; +1.323.308.1833 [work]; gedk@aidshealth.org
AHF East Coast: Imara Canady, National Director, Communications and Community Engagement, AHF
+1.470.639.6591 work; +1.770.940.6555 mobile; imara.canady@ahf.org

More News From AIDS Healthcare Foundation

AHF: Florida Budget Becomes Law, Securing Reversal of HIV Drug Cuts

TALLAHASSEE, Fla.--(BUSINESS WIRE)--AHF: Florida Budget Becomes Law, Securing Reversal of HIV Drug Cuts...

After UN HIV Meeting, AHF Calls for Resources to Match Promises

LOS ANGELES--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) welcomed the engagement of Member States at the 2026 United Nations High-Level Meeting on HIV/AIDS, while emphasizing that millions of people living with HIV still do not have access to lifesaving treatment, and an estimated 1.2 million people acquire HIV each year. As governments reaffirm their commitment to ending AIDS as a public health threat, AHF urged that political promises be matched by the resources needed to turn commitmen...

Hantavirus Reveals Latin America Is Unprepared, Warns The Lancet Commentary

MEXICO CITY--(BUSINESS WIRE)--The Latin American Technical Working Group, composed of former health ministers from the region, public health experts, epidemiologists, academics, and civil society representatives, published a new comment in The Lancet arguing that Latin America urgently needs a regional rapid-response platform to prevent, prepare for, and respond to infectious threats. Read the full text in The Lancet here. The comment, written collectively by the Technical Working Group, takes...
Back to Newsroom